Geron Ranked in Biotechnology Patent Scorecard Published in The Wall Street Journal

MENLO PARK, Calif.--(Business Wire)--
Geron Corporation (NASDAQ:GERN) was ranked number 5 of companies
listed in the biotechnology patent scorecard published in the Feb. 12
issue of The Wall Street Journal.

The ranking, which is based on the strength of Geron's science as
measured by the scale, quality, impact and nearness to the core
science of the company's intellectual property portfolio, reflects
Geron's dominant patent position in pioneering technologies including
an anti-cancer drug and vaccine targeting telomerase and cell
therapies being developed from the company's human embryonic stem cell
platform. Geron owns or licenses 34 issued U.S. patents, over 60
issued foreign patents and more than 230 patent applications that are
pending worldwide in the area of human embryonic stem cells. The
company owns or licenses 109 issued U.S. patents, over 170 issued
foreign patents and more than 160 patent applications that are pending
worldwide related to its telomerase technology.

"Our expansive intellectual property portfolio is a solid
foundation for our development of human embryonic stem cell-based
therapeutics and anti-cancer products that inhibit or target
telomerase," said Thomas B. Okarma, Ph.D., M.D., Geron's president and
chief executive officer. "More important than the number of filings,
the breadth and depth of the claim sets included in each patent
application, combined with where we are in product development,
protects our leadership position in two novel fields of science and
medicine. We are pleased to see the significance of our work and the
resulting patent filings recognized."

About Geron

Geron is developing first-in-class biopharmaceuticals for the
treatment of cancer and chronic degenerative diseases, including
spinal cord injury, heart failure and diabetes. The company is
advancing an anti-cancer drug and a cancer vaccine that target the
enzyme telomerase through multiple clinical trials. Geron is also the
world leader in the development of human embryonic stem cell-based
therapeutics, with its spinal cord injury treatment anticipated to be
the first product to enter clinical development. For more information,
visit www.geron.com.

This news release may contain forward-looking statements made
pursuant to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that statements
in this press release regarding potential applications of Geron's
human embryonic stem cell and telomerase technologies constitute
forward-looking statements that involve risks and uncertainties,
including, without limitation, risks inherent in the development and
commercialization of potential products, uncertainty of clinical trial
results or regulatory approvals or clearances, need for future
capital, dependence upon collaborators and maintenance of our
intellectual property rights. Actual results may differ materially
from the results anticipated in these forward-looking statements.
Additional information on potential factors that could affect our
results and other risks and uncertainties are detailed from time to
time in Geron's periodic reports, including the quarterly report on
Form 10-Q for the quarter ended September 30, 2007.

Russo Partners, LLC
Media and Investors:
David Schull, 858-717-2310
david.schull@russopartnersllc.com
or
Russo Partners, LLC
Tracey Milani, 619-814-3511
tracey.milani@russopartnersllc.com
or
Geron
David L. Greenwood, 650-473-7765
Chief Financial Officer
info@geron.com

Copyright Business Wire 2008